CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lukaka@cato-chem.com
Octreotide Acetate

醋酸奥曲肽 杂质对照品Octreotide Acetate Impurities

EP23 个杂质条目23 impurity entries

本页汇总 醋酸奥曲肽 的 23 个杂质对照品条目,其中药典杂质标注了 EP/USP 编号。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 23 impurity reference standards of Octreotide Acetate with EP/USP numbering where applicable. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 醋酸奥曲肽(Octreotide Acetate)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesImpact of octreotide counterion nature on the long-term stability and release kinetics from an in situ forming depot technology
    Journal of controlled release : official journal of the Controlled Release Society · 2021 · Molinier C et al.  ·  PMID 34214596  ·  DOI
  2. 杂质研究Impurity studiesLC determination of octreotide acetate in compound formulations of Sandostatin and diamorphine hydrochloride
    Journal of pharmaceutical and biomedical analysis · 1999 · Kyaterekera N et al.  ·  PMID 10703987  ·  DOI
  3. 分析方法Analytical MethodsOptimization and validation of the liquid chromatography coupled to tandem mass spectrometry method for assessing octreotide release from microspheres during inflammation in rabbit models
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences · 2023 · Wang G et al.  ·  PMID 36508900  ·  DOI
  4. 分析方法Analytical MethodsFacile spectrofluorimetric quantitation of octreotide, a synthetic peptide, in its pure form and pharmaceutical formulation; evaluation of the method's greenness
    Luminescence : the journal of biological and chemical luminescence · 2022 · Attia TZ et al.  ·  PMID 36044548  ·  DOI
  5. 分析方法Analytical MethodsQuantitative determination and validation of octreotide acetate using (1) H-NMR spectroscopy with internal standard method
    Magnetic resonance in chemistry : MRC · 2018 · Yu C et al.  ·  PMID 28921691  ·  DOI

醋酸奥曲肽 —— 原料药与杂质对照品Octreotide Acetate — drug substance & impurities

共 23 个条目(含原料药本体)23 items incl. the drug substance
Octreotide Acetate structure
EP原料药 APIAPI
醋酸奥曲肽Octreotide Acetate
Octreotide Acetate
CAS No.79517-01-4
Chemical FormulaC49H66N10O10S2·n(C2H4O2)
Purity>95%询价On request
10mg25mg50mg100mg
Octreotide Acetate Impurity 13 (Octreotide EP Impurity A) (6-D-Allothreonine Octreotide) structure
EPA
醋酸奥曲肽杂质13 (奥曲肽EP杂质A) (6-D-别苏氨酸奥曲肽)Octreotide Acetate Impurity 13 (Octreotide EP Impurity A) (6-D-Allothreonine Octreotide)
Octreotide Acetate Impurity 13 (Octreotide EP Impurity A) (6-D-Allothreonine Octreotide)
CAS No.1546983-12-3
Chemical FormulaC49H66N10O10S2
Purity>95%询价On request
10mg25mg50mg100mg
Octreotide Acetate Impurity 18(Octreotide EP Impurity B) structure
EPB
醋酸奥曲肽杂质18(奥曲肽EP杂质B)Octreotide Acetate Impurity 18(Octreotide EP Impurity B)
Octreotide Acetate Impurity 18(Octreotide EP Impurity B)
CAS No.1211530-36-7
Chemical FormulaC49H66N10O10S2
Purity>95%询价On request
10mg25mg50mg100mg
Octreotide Acetate Impurity 12 (Octreotide EP Impurity C) structure
EPC
醋酸奥曲肽杂质12 (奥曲肽EP杂质C)Octreotide Acetate Impurity 12 (Octreotide EP Impurity C)
Octreotide Acetate Impurity 12 (Octreotide EP Impurity C)
CAS No.1546983-16-7
Chemical FormulaC50H68N10O11S2
Purity>95%询价On request
10mg25mg50mg100mg
Octreotide Acetate Impurity 15 (Octreotide EP Impurity E) structure
EPE
醋酸奥曲肽杂质15(奥曲肽EP杂质E)Octreotide Acetate Impurity 15 (Octreotide EP Impurity E)
Octreotide Acetate Impurity 15 (Octreotide EP Impurity E)
CAS No.1546983-27-0
Chemical FormulaC49H66N10O10S3
Purity>95%询价On request
10mg25mg50mg100mg
Octreotide Acetate Impurity 6(Octreotide EP Impurity F) structure
EPF
醋酸奥曲肽杂质6(奥曲肽EP杂质F)Octreotide Acetate Impurity 6(Octreotide EP Impurity F)
Octreotide Acetate Impurity 6(Octreotide EP Impurity F)
CAS No.133304-81-1
Chemical FormulaC51H68N10O11S2
Purity>95%询价On request
10mg25mg50mg100mg
Octreotide Acetate Impurity 1 (Octreotide EP Impurity I)(D-Phe1(Ac) Octreotide) structure
EPI
醋酸奥曲肽杂质1(奥曲肽EP杂质I)(1位D-苯丙氨酸(乙酰基) 奥曲肽)Octreotide Acetate Impurity 1 (Octreotide EP Impurity I)(D-Phe1(Ac) Octreotide)
Octreotide Acetate Impurity 1 (Octreotide EP Impurity I)(D-Phe1(Ac) Octreotide)
CAS No.83795-61-3
Chemical FormulaC51H68N10O11S2
Purity>95%询价On request
10mg25mg50mg100mg
Octreotide Dihydrochloride structure
—
双盐酸奥曲肽Octreotide Dihydrochloride
Octreotide Dihydrochloride
CAS No.1607842-55-6
Chemical FormulaC47H66N10O10S2·2HCl
Purity>95%询价On request
10mg25mg50mg100mg
Octreotide Diacetate structure
—
奥曲肽 二醋酸盐Octreotide Diacetate
Octreotide Diacetate
CAS No.622838-44-2
Chemical FormulaC49H66N10O10S2·2(C2H4O2)
Purity>95%询价On request
10mg25mg50mg100mg
Octreotide Monomer structure
—Peptide
奥曲肽 单体Octreotide Monomer
Octreotide Monomer
D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-ol
CAS No.83150-76-9
Chemical FormulaC49H66N10O10S2
Purity>95%询价On request
10mg25mg50mg100mg
Octreotide Acetate Impurity 3 structure
3
醋酸奥曲肽杂质3Octreotide Acetate Impurity 3
Octreotide Acetate Impurity 3
CAS No.406217-48-9
Chemical FormulaC47H63N11O8S2
Purity>95%询价On request
10mg25mg50mg100mg
Octreotide Acetate Impurity 8 structure
8
醋酸奥曲肽杂质8Octreotide Acetate Impurity 8
Octreotide Acetate Impurity 8
CAS No.1546983-33-8
Chemical FormulaC51H68N10O11S2
Purity>95%询价On request
10mg25mg50mg100mg
Octreotide Acetate Impurity 11 structure
11
醋酸奥曲肽杂质11Octreotide Acetate Impurity 11
Octreotide Acetate Impurity 11
CAS No.1546983-18-9
Chemical FormulaC45H59N9O8S2
Purity>95%询价On request
10mg25mg50mg100mg
Octreotide Acetate Impurity 16 (Des-Thr-ol8 Octreotide) structure
16
醋酸奥曲肽杂质16 (去苏氨醇8 奥曲肽)Octreotide Acetate Impurity 16 (Des-Thr-ol8 Octreotide)
Octreotide Acetate Impurity 16 (Des-Thr-ol8 Octreotide)
CAS No.160841-00-9
Chemical FormulaC45H57N9O9S2
Purity>95%询价On request
10mg25mg50mg100mg
Octreotide Acetate Impurity 17 structure
17
醋酸奥曲肽杂质17Octreotide Acetate Impurity 17
Octreotide Acetate Impurity 17
CAS No.1926163-80-5
Chemical FormulaC98H132N20O20S4
Purity>95%询价On request
10mg25mg50mg100mg
Octreotide Acetate Impurity 21 structure
21
醋酸奥曲肽杂质21Octreotide Acetate Impurity 21
Octreotide Acetate Impurity 21
CAS No.183545-38-2
Chemical FormulaC49H66N10O10S
Purity>95%询价On request
10mg25mg50mg100mg
Octreotide Acetate Impurity 26 (L-Threoninol 8(Glycolic Acid) Octreotide) structure
26
醋酸奥曲肽杂质26 (L-苏氨醇8(乙醇酸) 奥曲肽)Octreotide Acetate Impurity 26 (L-Threoninol 8(Glycolic Acid) Octreotide)
Octreotide Acetate Impurity 26 (L-Threoninol 8(Glycolic Acid) Octreotide)
CAS No.1796598-13-4
Chemical FormulaC51H68N10O12S2
Purity>95%询价On request
10mg25mg50mg100mg
Octreotide Acetate Impurity 32 structure
32
醋酸奥曲肽杂质32Octreotide Acetate Impurity 32
Octreotide Acetate Impurity 32
CAS No.2821715-07-3
Chemical FormulaC55H74N10O14S2
Purity>95%询价On request
10mg25mg50mg100mg
Octreotide Acetate Impurity 33 structure
33
醋酸奥曲肽杂质33Octreotide Acetate Impurity 33
Octreotide Acetate Impurity 33
CAS No.2821715-05-1
Chemical FormulaC55H74N10O14S2
Purity>95%询价On request
10mg25mg50mg100mg
Octreotide Acetate Impurity 36 structure
36
醋酸奥曲肽杂质36Octreotide Acetate Impurity 36
Octreotide Acetate Impurity 36
CAS No.774239-80-4
Chemical FormulaC52H73N11O11S2
Purity>95%询价On request
10mg25mg50mg100mg
Octreotide Acetate Impurity 41(6-D-Thr Octreotide) structure
41
醋酸奥曲肽杂质41(6-D-苏氨酸奥曲肽)Octreotide Acetate Impurity 41(6-D-Thr Octreotide)
Octreotide Acetate Impurity 41(6-D-Thr Octreotide)
CAS No.87759-89-5
Chemical FormulaC49H66N10O10S2
Purity>95%询价On request
10mg25mg50mg100mg
Octreotide Acetate Impurity 42 ([Des-Thr-ol8]-Cys7-amide-Octreotide) structure
42
醋酸奥曲肽杂质42 ([去-苏氨酸-ol8]-半胱氨酸7-酰胺-奥曲肽)Octreotide Acetate Impurity 42 ([Des-Thr-ol8]-Cys7-amide-Octreotide)
Octreotide Acetate Impurity 42 ([Des-Thr-ol8]-Cys7-amide-Octreotide)
CAS No.79486-60-5
Chemical FormulaC45H58N10O8S2
Purity>95%询价On request
10mg25mg50mg100mg
Octreotide Acetate Impurity 44 (Hynic-(Tyr3) Octreotide) structure
44
醋酸奥曲肽杂质44 (6-肼基烟酸-(酪氨酸3) 奥曲肽)Octreotide Acetate Impurity 44 (Hynic-(Tyr3) Octreotide)
Octreotide Acetate Impurity 44 (Hynic-(Tyr3) Octreotide)
CAS No.257943-19-4
Chemical FormulaC55H71N13O12S2
Purity>95%询价On request
10mg25mg50mg100mg

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

醋酸奥曲肽 —— 研究文献与合成路线Octreotide Acetate — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 醋酸奥曲肽 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Octreotide Acetate. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. Pore change during degradation of octreotide acetate-loaded PLGA microspheres: The effect of polymer blends
    Wang T, Xue P, Wang A, et al. · European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · 2019 · 被引 29cited 29

合成与制备工艺专利Synthesis & process patents

  1. Prepn process of octreotide acetate
    YAN LI SONG · 公开号 CN1810829CN1810829 · 2006
  2. Solid-phase synthesis process of octreotide acetate
    JIA ZHIDAN, WANG ENZI · 公开号 CN1569890CN1569890 · 2005

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

醋酸奥曲肽 杂质谱研究要点Octreotide Acetate — impurity profiling notes

下面这些是拿到 醋酸奥曲肽 的 23 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 23 impurity entries for Octreotide Acetate, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

本品种含药典编号杂质(EP/USP)。申报时药典已收载的杂质通常需要逐项对照,建议优先备齐药典编号对照品,再补充工艺与降解杂质。This drug substance includes pharmacopoeially designated impurities (EP/USP). Monographed impurities normally need item-by-item comparison during filing, so secure the pharmacopoeial standards first, then fill in process and degradation impurities.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances